Details of the Drug
General Information of Drug (ID: DM8PBEJ)
| Drug Name | 
                     4-Hydrazinocarbonyl-benzenesulfonamide 
                 | 
            ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | 
                                         
                        4-(hydrazinecarbonyl)benzenesulfonamide; 35264-29-0; 4-(hydrazinecarbonyl)benzene-1-sulfonamide; JIDAHYHCQJXNTD-UHFFFAOYSA-N; 4-(hydrazinylcarbonyl)benzenesulfonamide; 4-   benzenesulfonamide; 4-HYDRAZINOCARBONYL-BENZENE-SULFONAMIDE; hydrazide 2; p-Sulfamylbenzoic acid hydrazide; AC1L7XIP; CHEMBL180323; SCHEMBL4616920; BDBM12136; CTK4H4135; DTXSID60312358; 4-Sulfamoylbenzoic acid hydrazide; MolPort-000-887-192; ZINC1556993; STK349231; SBB021016; 4376AB; NSC252930; AKOS000305291; MCULE-5832659214
                        
                     
                                     | 
            ||||||||||||||||||||||
| Indication | 
                                                            
  | 
            ||||||||||||||||||||||
| Drug Type | 
                     Small molecular drug 
                 | 
            ||||||||||||||||||||||
| Structure | 
                    ![]()  | 
            ||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 215.23 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -1.1 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
| Chemical Identifiers | 
                        
  | 
                ||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT)  | 
                
                    
  | 
            ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||||||||
                    
  | 
            ||||||||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||||||||


